Pharmaceutical Executive Daily: Eli Lilly Enters $2.8 Billion Agreement to Acquire Merida Biosciences

Eli Lilly agrees to acquire Merida Biosciences for up to $2.875 billion, BioNTech halts a Phase II trial of its cancer immunotherapy Cevumeran, and Parth Khanna argues that more competitive data doesn't mean better intelligence in pharma.